Intranasal cocaine abuse can lead to destruction of the palat e and p erforation of the nasal septum. The path ophysiology of cocaine-induced midline destru ctiv e lesions is multifactorial and includes local ischemia secondary to vasoconstri ction, chemical irritationfroin adulterants put in "cut" cocaine, and infection seco ndary to trauma , impair ed mu cociliary transport, and decreased humoral and cell-mediated immunity. Cocain e abuse should be suspected in patients with a palatal or septal pel/ orat ion of unkn own etiology .
tial side effects (see "Questions arise over the use of cocaine in rhinologic practice," page 176).
In this article , we describe the cases of two patients who were seen during August 1997 at the Manhattan (N.Y.) Eye, Ear , and Throat Hospit al. Both patients had experienced osteocartilaginous necro sis secondary to coc aine abu se. We also review the pathophy siology and differential diagnosis of a cocaine-indu ced midline destructive lesion (CIMDL), and we discuss alternatives to the use of cocaine in rhinologic practic e.
Case reports
Patient 1. We ev alu ated a 47-year-old woman who had a 14-year history of intranasal use of street coca ine that had begun in 1983. She des cribed her early use as recreational , using 0.5 gram s "a couple of time s a month" durin g the first 4 years. During this time , she began to experience hypernasal speech, nasal obstruction, anosmia, and a diminished sense of taste.
Her cocaine intake incre ased dram atically durin g the next 2 years to between 0.5 and 2.0 g/day, and in 1989 she began to experience intermittent epi staxis, chronic facia l and periorbital pain, purulent nasal disch arge, and episodes of fever associated with sore thro at and swoll en neck glands. She rec alled that durin g this peri od, "pieces of cartilage and small bits of bone " would fall from her 'nose when she cleaned it with a Q-Tip. Despite the severe disc omfort that this cau sed, she did not seek pro fessional med ical care. She later becam e pregnant and quit using cocaine, but by 1996 she had resumed snorting 1.0 to 1.5 g/day. During the year prior to her visit, she began to notice a defect in her hard palate alon g with oronasa l regurgitation of both solids and liquids.
In July 1997, she finally sought medical attention for facial swelling. After she did not respond to a 2-week trial of oral amoxi cillin/clavulanate , she was admitted to the hospital with a dia gno sis of facial cellulitis. On admi ssion, she disclosed the nature of her coc aine abu se. Ex-
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Schering Corporation
Patient 2. A 44-year-old woman who was a known cocaine abuser reported a 2-day history of left facial swelling associated with fever and chills. She was diagnosed with left facial cellulitis. On physical examination, we noted a nasal septal perforation and a large amount of nasal crusting. Laboratory tests revealed that her white blood cell count was elevated (13, 100/mm 3 ) and that her nasal cultures were positive for Staphylococcus aureus. She was also positive for c-ANCA (140 D/ml), and her ESR was elevated. Findings on chest x-ray were normal.
After the patient failed to improve on intravenous antibiotics (metronidazole, ampicillinlsulbactam, and gentamicin) and nasal spray irrigations with saline and mupirocin, she was taken to the operating room. Endoscopy was performed to debride the nasal cavity and to obtain several biopsy specimens. A number of these specimens contained evidence of necrotic granulation tissue without vascular involvement.
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Discussion
The first case of nasal septal perforation secondary to cocaine use was reported by Owens in 1912. 6 ,7 In 1997, Helie and Fournier reported that 17 cases of CIMDL had been described in the literature, four of which had involved the hard palate." Two other case reports have been published-one of a patient who had only a nasal septal perforation? and one of a patient who had a nasal septal perforation and an oronasal fistula." We suspect that the incidence of these lesions is greater than what has thus far been reported because many cocaine abusers who have a CIMDL do not seek medical attention.
For the purpose of this article, a patient is considered to have a CIMDL if he or she has at least two of these three conditions: (1) a nasal septal perforation, (2) lateral nasal wall destruction of the inferior or middle turbinate in the maxillary or ethmoid sinus, or (3) hard palate involvement, either clinically or radiographically.
Pathophysiology. Several factors are involved in the pathophysiology of a CIMDL. They include local ischemia secondary to vasoconstriction, chemical irritation from adulterants put in "cut" cocaine, and infection secondary to trauma, decreased humoral and cell-mediated immunity, and impaired mucociliary transport:
• Ischemia. The potent vasoconstricting properties of cocaine can induce ischemic necrosis of cartilage and mucosa. In addition, ischemia is often aggravated when abusers also use an over-the-counter vasoconstrictor to prevent the associated rebound hyperemia and thereby prolong the "high."8.10
• Chemical irritation. Pure cocaine is diluted with a wide variety of substances before it is sold on the street. These adulterants include mannitol, dextrose, lactose, inositol (a vitamin B compound), lidocaine, procaine, quinine, caffeine, talc, plaster of Paris, amphetamines, salicylamide, borax, Epsom salts, and heroin. 1.6.8,9 When snorted, lactose can cause postnasal drip, inositol can SMITH, KACKER , ANAND cause rhinitis, lidocaine and procaine can cause facial numbness, and quinine can cause tinnitus, nausea, headache, and visual impairment. !" «Infection. Local trauma with superinfection can occur when a cocaine abuser picks at his or her nose with an instrument such as a pen or pencil to relieve discomfort by "scratching the itch. "
In addition, we also believe that cocaine's effect on both the immune system and nasal mucociliary transport rates plays an important role in the pathophysiology of CIMDL, although this is not generally stated in the literature. Researchers have shown that cocaine suppresses immune function in mice by decreasing phagocytosis, antibody function, and natural killer-cell and cytotoxic T-cell activity ." These decreases result in an increase in tumor growth and a lowering of resistance to various viruses . Wu et al determined how cocaine injected into mice alters the activity of the thymus and influences T-lymphocyte maturation. 12 Their analysis revealed that apoptosis of different subpopulations of T lymphocytes increased as the dosage of cocaine increased.
Cocaine also impairs the body's defense mechanisms against infection by slowing nasal mucociliary transport rates . The nasal mucociliary system moves foreign particles trapped in the mucus of the nose to the nasopharynx , .where they can be either swallowed or expectorated. 13 Mucociliary clearance can be monitored by analyzing ciliary beat frequency with in vitro testing. " Human nasal mucociliary transport rates can be determined by tracing radioactive particles or the clearance times of colored dyes or saccharin from the anterior end of the inferior turbinate to the oropharynx." It has been demonstrated that normal mucociliary clearance takes less than 20 minutes ." Ingels et al found that cocaine decreased ciliary beat frequency at concentrations of 1.75 % and greater. 15 Mason et al!' found that 2.5 % cocaine decreased the mucociliary transport rate by 58 %, and Ingles et al" also found that partially reversible cilia stasis occurs with 7.0% cocaine. This latter finding was in agreement with those of earlier studies th at showed that 10.0 % cocaine is likely to produce irreversible cilia stasis. P:" It is therefore logical to assume th at the snorting of street cocaine significantly impairs the mucociliary system. The histopathology seen in most patients with sinonasal tract necrosis following cocaine abuse is consistent with infection and positive cultures. The most common infectious agent is S aureus, which was isolated in our patient 2. 16 Symptoms. The history and symptoms of the two patients described in this report were similar to those reported by several other authors who examined the detrimental effects of cocaine abuse on the sinonasal tract. 1.6.1 6.17 Common sympto ms of intranasal snorting are excessive sniffing, epistaxis, nasal crusting, a diminished sense of smell and/or taste, sinus infection, frontal headache, nasal 174 obstruction, perforation of the nasal septum and hard palate, and saddle-nose deformity .1.9.17 Other medical complications of cocaine use include myocardial infarction, cardiac arrhythmias, hypertension, aortic rupture, stroke, clonic-tonic convulsions, septicemia with endocarditis and hepatitis , pulmonary insufficiency, and psychiatric disturbances.F:'? The incidence of osteocartilaginous necrosis is not clear.
Diagnosis.
A CIMDL should be considered in the differential di agnosis of any patient who has any of these sympto ms that cannot be explained. The primary differential diagnoses include Wegener's granulomatosis , sinonasallymphomas and other primary neoplasms of the paranasal sinuses , collagen vascular disease, and sinusitis with osteitis secondary to cocaine use . Identification of the specific etiology of midline nasal destruction and perforationis critical to successful management because therapy is quite specific. At one time, the infectious causes of nasal perforation included tuberculosis, typhoid, diphtheria, tertiary syphilis, and leprosy. However, as noted by Kuriloff and Kimmelman, these causes have become exceedingly rare since the introduction of antibiotics ."
The work-up should include a chest x-ray to rule out pulmonary infiltrates and laboratory testing to measure the ESR and levels of ANA, c-ANCA, and rheumatoid factor. Various authors have also recommended measuring angiotensin-converting enzyme, 6 fluorescent treponemal antibody-absorbed;" purified protein derivative," and creatinine'? levels. Multiple biopsies should be performed to rule out other causes of midline destruction and to ensure that life-threatening but treatable diseases such as Wegener's granulomatosis are not missed. t" Many authors once listed polymorphic reticulosis, malignant midline reticulosis, lymphomatoid granulomatosis, malignant destructive granuloma, and idiopathic midline destructive di sease as separate entities in the etiology of midfacial necrotizing lesions. v":" However, advances in immunocytochemistry phenotyping and molecular genetics have shown that most of these lesions are lymphomas of the sinonasal tract."
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Questions arise over the use of cocaine in rhinologic practice
The use of cocaine in rhinologic practice has come under scrutiny because of its potential for abuse , its cost, and its side effects.v" Side effects are the result of cocaine's ability to potentiate sympathetic nerve stimulation. In severe cases, this stimulation can result in cardiac arrhythmias , myocardial infarction {MIl. highoutput congestive heart failure, hypertension, aortic dissection, aortic rupture, intracerebral hemorrhage, and clonic-tonic convulsions."
Feehan and Mancusi Ungaro obtained questionnaire responses from 741 surgeons who had administered cocaine during submucous resection and rhinoplasty procedures {total number of cases : 93,004).22 Among these cases were 233 mild react ions to cocaine (resuscitation not requ ired), 32 severe reactions (resuscitation required) , and five deaths.
Vasoconstriction of the coronary arteries is the primary contributor to cocaine-induced M1.21,23 MI can occur as a result of cocaine use alone or from the combined use of cocaine and either epinephrine or phenylephrine. Ashchi et al reported the case of a 23year-old woman without coronary artery disease who experienced an acute non-Q-wave MI after she had rece ived cocaine anesthesia during an elective nasal septoplasty." For hemostasis, cotton pledgets soaked in phenyleph rine had been placed in her nose prior to extubation.
There is no other sing le substance that provides cocaine's unique dual effect of vasoconstriction and anesthesia.v-" But in light of its potential risks, researchers have looked for alternatives to cocaine anesthesia. Several authors have studied the effects of combining a trad itional vasoconstrictor and an anesthetic.v -" Tarver et al found that a lidocaine and oxymetazoline combination is a stronger vasoconstrictor than cocaine and provides equally good anesthes ia," Lennox et al found that co-phenylcaine fortea new preparation that comb ines lidocaine, phenylephrine, and benzylkonium-provided degrees of vasoconstriction and local anesthesia in the nasal mucosa that were similar to those provided by cocaine." The lidocaine provides effective anesthes ia, the phenylephrine induc es vasoconstriction, and the benzylkonium is a preservative. In another study, Kasemsuwan and Griffiths reported that the combination of lidocaine and adrenaline was as effective as cocaine.'
The abuse potential of cocaine, its potential to cause serious adverse reactions, and the availability of anesthetic and vasoconstriction substitutes should clearly influence our decisions regarding the use of cocaine in otolaryngology.
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granulomatous vasc ulitis. Moreover, patient 2 did not have any evi dence of pulmo nary or renal disease. The refore , based on both the histopath ologic findings and the clinical pictur e, we co ncluded that the c-ANC A finding in this case was a false positive. Arms trong and Shi kani repor ted a very similar case.' They treated a known coc aine abuser who had a nasal septal perforation , an oronasal fis tula, and a positive c-ANCA test. Aft er obtaining an appropriate biopsy and consulting with the rheum atology service , they like wise concluded that the c-ANCA finding was a false positive and that their patient did not have Wegener ' s gra nulomatosis .
Therefore, it does not appear that a positive c-ANCA without appropriate histopathologic findings is diagno stic of Wegener' s granulomatosis in this patient population. Again , to make a definitive determ ination , it is clearl y impor tant to perform multiple biopsies until an adequ ate sample can be obtained to allow for an appropriate tissue analysis.
Stud ies have shown that treatm ent of Wegener ' s granulomatosis with cyclophosphamide and predn isone result s in a compl ete rem ission in more than 75% of patient s and a marked imp rovement in another 15%.20 01TI\7El\Il .
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